866-997-4948(US-Canada Toll Free)

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Nov 2015

Category :

Cancer

No. of Pages : 57 Pages

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2015

Summary

Global Markets Directs, Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2015, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies 9
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Investigation by Universities/Institutes 10
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Investigation by Universities/Institutes 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 16
Arbutus Biopharma Corporation 16
ArQule, Inc. 17
EnGeneIC Ltd 18
Marathon Pharmaceuticals, LLC 19
Merck KGaA 20
Orphagen Pharmaceuticals, Inc. 21
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
ARQ-087 - Drug Profile Product Description 31
Mechanism of Action 31
R&D Progress 31
ATR-101 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
avelumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody Conjugate to Target B7-H3 for Cancer - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MP-110 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TargomiRs - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TKM-PLK1 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Recent Pipeline Updates 42
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 49
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 50
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 51
Featured News & Press Releases 51
Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015 51
Dec 31, 2014: Tekmira Provides Update on TKM-PLK1 Phase I/II Clinical Study in Patients With Advanced Gastrointestinal Neuroendocrine Tumors and Adrenocortical Carcinoma 51
Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers 52
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 52
Oct 08, 2013: Tekmira Provides Corporate Update On Oncology Product Candidate TKM-PLK1 53
Aug 12, 2013: Tekmira commences Phase I/II study of TKM-PLK1 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2015 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Arbutus Biopharma Corporation, H2 2015 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule, Inc., H2 2015 17
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by EnGeneIC Ltd, H2 2015 18
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015 19
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H2 2015 20
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015 21
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Stage and Target, H2 2015 24
Number of Products by Stage and Mechanism of Action, H2 2015 26
Number of Products by Stage and Route of Administration, H2 2015 28
Number of Products by Stage and Molecule Type, H2 2015 30
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics - Recent Pipeline Updates, H2 2015 42
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2015 49
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2015 50

List of Figures
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2015 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 12
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Targets, H2 2015 23
Number of Products by Stage and Targets, H2 2015 23
Number of Products by Mechanism of Actions, H2 2015 25
Number of Products by Stage and Mechanism of Actions, H2 2015 25
Number of Products by Routes of Administration, H2 2015 27
Number of Products by Stage and Routes of Administration, H2 2015 27
Number of Products by Molecule Types, H2 2015 29
Number of Products by Stage and Molecule Types, H2 2015 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *